Percutaneous coronary intervention in octogenarians and the safety of glycoprotein IIb/IIIa inhibitors

Bleeding outcomes after non-emergency percutaneous coronary intervention in the very elderly

Background

Octogenarians constitute an increasing proportion of patients presenting for non-emergency percutaneous coronary intervention (PCI).

Methods

This study evaluated the in-hospital procedural characteristics and outcomes, including the bleeding events of 293 octogenarians presenting between January 2010 and December 2012 for non-emergency PCI to a single large volume tertiary care Australian center. Comparisons were made with 293 consecutive patients aged less than or equal to 60 years, whose lesions were matched with the octogenarians.

Results

Non-ST elevation myocardial infarction was the most frequent indication for non-emergency PCI in octogenarians. Compared to the younger cohort, they had a higher prevalence of co-morbidities and more complex coronary disease, comprising more type C and calcified lesions. Peri-procedural use of low molecular weight heparin (LMWH; 1.0% vs. 5.8%; P < 0.001) and glycoprotein IIb/IIIa inhibitors (2.1% vs. 9.6%; P < 0.001) was lower, while femoral arterial access was used more commonly than in younger patients (80.9% vs. 67.6%; P < 0.001). Overall, there was a non-significant trend towards higher incidence of all bleeding events in the elderly (9.2% vs. 5.8%; P = 0.12). There was no significant difference in access site or non-access site bleeding and major or minor bleeding between the two cohorts. Sub-analysis did not reveal any significant influence on bleeding rates by the use of LMWH, glycoprotein IIb/IIIa inhibitors or femoral arterial access. In addition, there were no significant differences in the rates of in-hospital mortality, stroke or acute stent thrombosis between the two groups.

Conclusions

In this single center study, we did not observe significant increases in adverse in-hospital outcomes including the incidence of bleeding in octogenarians undergoing non-emergency PCI.

Comparison of 30-Day and Long-Term Outcomes and Hospital Complications Among Patients Aged <75 Versus ≥75 Years With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Our aim was to evaluate the mortality rate and occurrence of complications in patients aged <75 versus ≥75 years with ST-elevation myocardial infarction (STEMI). We studied 1,657 consecutive patients with STEMI hospitalized in the cardiac intensive care unit during 2008 to 2014. All patients underwent primary percutaneous intervention, of which 292 (18%) were aged ≥75 years. Patient records were evaluated for in-hospital complications, 30-day mortality, and long-term mortality over a mean period of 3.4 ± 2.1 years. Compared with younger patients, patients aged ≥75 years had a significantly higher rate of coronary disease risk factors, prolonged symptom duration (512 ± 640 vs 333 ± 545 minutes, p <0.01) and door-to-balloon time (51.1 ± 24 vs 45.6 ± 38, p = 0.02). Patients aged ≥75 years had more in-hospital noncardiac and cardiac complications, including cardiogenic shock and arrhythmia, and had higher 30-day and long-term mortalities. Cardiogenic shock was associated with increased short- and long-term mortality in the older group but was not incremental over the noncardiogenic shock cohort. In conclusion, in patients aged ≥75 years who underwent primary percutaneous intervention for STEMI, the short- and long-term mortality rate was greater than fourfold higher compared with younger patients.

Results of percutaneous coronary interventions in patients ≥90 years of age

BACKGROUND

There are few data about percutaneous coronary interventions (PCI) in nonagenarians (patients aged > or =90 years). This study aimed to assess acute and intermediate term clinical outcomes among nonagenarian patients undergoing PCI.

METHODS

The study included 65 consecutive patients, age > or =90 years undergoing PCI between January 2001 and August 2006. Fourteen patients were admitted with acute ST elevation acute myocardial infarction (STEAMI), one had cardiogenic shock, 39 patients sustained non-STEAMI, and 12 patients were with severe stable angina pectoris. Procedural data, in-hospital, and six-month clinical outcomes were obtained and adjudicated for all patients.

RESULTS

Coronary angiography documented multivessel disease in 86% of patients with relatively complex lesions (type B or C) in 94% treated using stent deployment in 92% of patients. In 7% of cases IABP was needed. Immediate procedural success was achieved in 92% patients. Cumulative mortality at hospital discharge and by 30-days was 14% and increased to 18% at 6-months follow-up. Total major adverse cardiac events (MACE: death, AMI, TVR, stroke) was 17% at hospital discharge and increased to 21% by 6-months. Stroke was documented in one patient (1.5%) at hospital discharge. Cumulative mortality at 6 month was 0% in patients with stable angina and 23% in emergent PCI scenario (AMI or NSTEAMI or ACS). Univariate analysis revealed that emergent PCI, systolic blood pressure, left ventricular ejection fraction, diabetes mellitus, renal failure, TIMI flow at baseline, and procedural success, are all correlative with 6-months mortality.

CONCLUSION

We conclude that clinically stable nonagenarian patients with coronary artery disease undergoing PCI have excellent PCI related prognosis while clinically unstable patients have a worse outcome. Thus, careful attention to background medical history and clinical presentation should dictate the prognosis and/or management among nonagenarian patients.

Effectiveness of sirolimus-eluting stent implantation for the treatment of coronary artery disease in octogenarians

Sirolimus-eluting stent (SES) implantation has been shown to reduce repeat revascularization in various randomized trials. The present study evaluated the outcomes after SES implantation in 46 octogenarian patients. SES implantation in octogenarians appears to be feasible and is associated with very small subsequent need for repeat target vessel revascularization at 1 year.

State of the science for care of older adults with heart disease

This article provided an overview of the current state of knowledge related to cardiovascular disease in elders. Some depth has been provided related to CHD and HF, two common diagnoses in older persons. The most striking finding is that although trials are increasingly including older cohorts of patients, research specifically testing known therapies in older patients is essential. In particular, research testing the safety, efficacy, and acceptability of therapies in the oldest old is greatly needed.

Cardiac surgery in octogenarians and beyond

Should we do it, is it worthwhile, and who should decide?